Online inquiry

IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13137MR)

This product GTTS-WQ13137MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets APP gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13137MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13537MR IVTScrip™ mRNA-Anti-MCAM, PRX-003(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PRX-003
GTTS-WQ9915MR IVTScrip™ mRNA-Anti-CSF2, KB-003(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA KB-003
GTTS-WQ11634MR IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MGD-013
GTTS-WQ6312MR IVTScrip™ mRNA-Anti-TNFRSF10B, CS-1008(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CS-1008
GTTS-WQ13789MR IVTScrip™ mRNA-Anti-S, REGN-10933(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA REGN-10933
GTTS-WQ13189MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PF-04950615
GTTS-WQ3393MR IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AT-005
GTTS-WQ3596MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BAY 1129980
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW